ADVANCING MEDICINES TO IMPROVE THE TREATMENT OF DISEASE
Touchlight's technology: dbDNA™
A MINIMAL LINEAR DNA VECTOR
MADE WITH ENZYMES
Touchlight DNA Services
Contract manufacturing services for production of GMP dbDNA™ as a starting material for advanced therapy productionLearn more
Discovery and development of dbDNA™-based vaccines and gene therapy products to address diseases of high unmet needLearn More
Bringing together Touchlight’s technology with a team of vaccine development and infectious and respiratory disease experts, this program seeks to augment the existing vaccine development landscape as clinical data is released and understanding of SARS-CoV-2 continues to grow.
Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Touchlight’s ongoing work towards the COVID-19 response has been featured today in Martin Vander Weyer’s article in The Spectator: How entrepreneurs have turned to face this crisis.